Cortellis, the suite of life science intelligence solutions from Clarivate Analytics, unlocks hidden insights in data to accelerate innovation. Cortellis curates broad and deep sources of intelligence to enable precise, actionable answers to specific questions across the R&D lifecycle — from discovery and clinical development through regulatory submission and commercialization. See how in this video.
Combine Cortellis Deals and Competitive Intelligence for the essential data foundation and advanced analytics to get to the optimal deal faster. On a single platform, you can access extensive pipeline and company information, detailed deals information and analytical tools to compare and negotiate deals more effectively. See how in this video.
Cortellis Regulatory Intelligence unravels the complex regulatory landscape to drive strategic decisions and ensure your teams are aware of new regulations and changes to existing guidelines. As an integral part of your workflow, Cortellis Regulatory Intelligence curates information from global authorities to help companies stay compliant, increase submission approval rates, and successfully launch in markets worldwide. See how in this video.
Newport unlocks hidden insights in market, patent and API data to grow generics and API businesses. Newport curates the critical data you need to strategically develop your portfolio, find API suppliers, and identify potential partners. See how in this video.
Our patent-pending algorithm behind Drug Timeline & Success Rates uses statistical modeling and machine learning to generate more accurate pipeline forecasts in just a few clicks. When tested against conventional benchmark models, our forecasts proved to be 25% more accurate. See how in this video.
The growth of orphan drug development has led to steadily increasing investment, but is it viable for rare disease R&D to continue to grow?
Jamie Munro is joined by guest speaker, Tom Kassberg, from Ultragenyx, a biopharma company dedicated to developing therapies for rare diseases, to discuss the latest trends and implications for the pharmaceutical and biotech industries.
Part 2 continues the conversation around orphan drug investment, taking a closer look at the biggest players, as well as challenges and opportunities to increase R&D investment as the marketplace continues to evolve.
Over the last 10 years, the nature and types of drugs achieving blockbuster status has evolved. In this episode, we look at the seven drugs the Life Sciences Forecasting team at Clarivate Analytics predicts will be blockbusters by 2023 — and the key trends redefining the blockbuster model. Charlotte Jago, Ph.D., senior editor, Cortellis, and Anette Breindl, Ph.D., senior science editor at BioWorld, share fresh insights on what’s influencing blockbuster status, including pricing, innovations in gene therapy, and global market dynamics.
Autoimmunity and allergy conditions have received considerable attention by drug developers in recent years. The Life Sciences Forecasting Team at Clarivate Analytics has predicted new treatments for conditions such as rheumatoid arthritis, peanut allergies and psoriasis to reach blockbuster status by 2023. Join Sarah Hardison, Ph.D., Therapeutic Area Director, and Joan Tur, Ph.D., editor, Cortellis, for an insightful discussion on the competitive landscape, commercial opportunities and the unique challenges facing autoimmunity and excessive immune drug developers.